Cannabinol (CBN; 30 and 300 mg) effects on sleep and next-day function in insomnia disorder (‘CUPID’ study): protocol for a randomised, double-blind, placebo-controlled, cross-over, three-arm, proof-of-concept trial

OBJECTIVE: Insomnia is the most prevalent sleep disorder, with few effective pharmacotherapies. Anecdotal reports and recent preclinical research suggest that cannabinol (CBN), a constituent of Cannabis sativa derived from delta-9-tetrahydrocannabinol, could be an effective treatment. Despite this,...

Descripción completa

Detalles Bibliográficos
Autores principales: Lavender, Isobel, McCartney, Danielle, Marshall, Nathaniel, Suraev, Anastasia, Irwin, Chris, D'Rozario, Angela L, Gordon, Christopher J, Saini, Bandana, Grunstein, Ronald R, Yee, Brendon, McGregor, Iain, Hoyos, Camilla M
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2023
Materias:
Research Methods
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10450062/
https://www.ncbi.nlm.nih.gov/pubmed/37612115
http://dx.doi.org/10.1136/bmjopen-2022-071148

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10450062/
https://www.ncbi.nlm.nih.gov/pubmed/37612115
http://dx.doi.org/10.1136/bmjopen-2022-071148

Ejemplares similares